Pharmaceutical

Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07275315?

PF-07275315 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).

Apr 17, 2024 - 00:00
PF-07275315 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Enliven Therap...

Next Article

Risk adjusted net present value: What is the current valuation of Eli Lilly and ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How did hiring in the Chinese pharma industry perform in Q2 2023

How did hiring in the Chinese pharma industry perform i...

Jul 29, 2023

STAT+: The lessons of Aduhelm, Biogen’s Alzheimer’s drug that was not to be

STAT+: The lessons of Aduhelm, Biogen’s Alzheimer’s dru...

Feb 3, 2024

AstraZeneca reports positive Phase III results for Imfinzi in small cell lung cancer

AstraZeneca reports positive Phase III results for Imfi...

Apr 7, 2024